Results: 3

1.
Fig 3

Fig 3. From: Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers.

Best percent change from baseline in target lesion size for patients who have at least postbaseline efficacy assessment.

Alex A. Adjei, et al. J Clin Oncol. ;26(13):2139-2146.
2.
Fig 2

Fig 2. From: Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers.

Percent change from baseline at day 15 (± 7 days) in (A) tumor cell nuclei H-score for pERK and (B) proportion of tumor cell nuclei staining for Ki-67. Patients received 100 mg bid or 200 mg bid (denoted by *).

Alex A. Adjei, et al. J Clin Oncol. ;26(13):2139-2146.
3.
Fig 1

Fig 1. From: Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers.

Immunostains of pre- and post-treatment melanoma specimens from the same patient. (A) Before dose, tumor cells are reactive to anti-pERK antibody (brown staining; magnification, ×100). (B) After dose, cells are unreactive to same anti-pERK antibody (magnification, ×100). (C) Before dose, variable nuclear Ki-67 labeling (approximately 30% positive nuclei; magnification, ×400). (D) After dose, marked reduction in nuclear Ki-67 labeling (< 1% positive nuclei; magnification, ×400)

Alex A. Adjei, et al. J Clin Oncol. ;26(13):2139-2146.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk